S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
This Stock Could Go Up 66% or More. (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
This Stock Could Go Up 66% or More. (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NYSE:CANF

Can-Fite BioPharma (CANF) Stock Forecast, Price & News

$2.65
+0.14 (+5.58%)
(As of 09/29/2023 ET)
Compare
Today's Range
$2.47
▼
$2.69
50-Day Range
$2.49
▼
$3.03
52-Week Range
$1.52
▼
$9.00
Volume
2,739 shs
Average Volume
9,938 shs
Market Capitalization
$9.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media

Can-Fite BioPharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
768.0% Upside
$23.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Can-Fite BioPharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.57) to ($0.95) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

See Top Rated MarketRank™ Stocks Here

CANF stock logo

About Can-Fite BioPharma (NYSE:CANF) Stock

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CANF Price History

CANF Stock News Headlines

September 27, 2023 | finance.yahoo.com
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
September 27, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)
October 1, 2023 | Chaikin Analytics (Ad)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
September 7, 2023 | finance.yahoo.com
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
September 1, 2023 | seekingalpha.com
Can-Fite Biopharma discloses $100M mixed shelf offering - filing
August 31, 2023 | finance.yahoo.com
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
August 24, 2023 | businesswire.com
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating ...
August 24, 2023 | finance.yahoo.com
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
October 1, 2023 | Altimetry (Ad)
WARNING: Seven millionaires to trigger sudden market panic?
The next major selloff could be just days away…And seven powerful (yet completely unknown) insiders will be behind it all – and help corporate executives make a killing as it plays out. Here’s the full story.
August 18, 2023 | markets.businessinsider.com
Can-Fite Submits Pediatric Study Plan To Allow Registration Of Piclidenoson
August 18, 2023 | finance.yahoo.com
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
July 17, 2023 | finance.yahoo.com
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
July 11, 2023 | finance.yahoo.com
Presenting on the Emerging Growth Conference on July 12 & 13 Register Now
July 7, 2023 | finance.yahoo.com
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
June 29, 2023 | finance.yahoo.com
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
June 27, 2023 | thestreet.com
Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data
June 13, 2023 | msn.com
CANF Rises on IND Submission Plans in Pancreatic Cancer
June 13, 2023 | markets.businessinsider.com
Can-Fite To Seek FDA Clearance For Phase II Trial Of Namodenoson In Pancreatic Cancer
June 13, 2023 | finance.yahoo.com
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
June 2, 2023 | finance.yahoo.com
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
June 1, 2023 | finance.yahoo.com
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
May 30, 2023 | finance.yahoo.com
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
May 15, 2023 | benzinga.com
Can-Fite: Presenting Namodenoson's New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
May 15, 2023 | finance.yahoo.com
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
May 11, 2023 | markets.businessinsider.com
Pre-market Movers: GFAI, SONO, KLXE, CDNA, DMRC…
May 10, 2023 | finance.yahoo.com
All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy
May 2, 2023 | finance.yahoo.com
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
See More Headlines
Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CANF Company Calendar

Last Earnings
8/31/2023
Today
9/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:CANF
CUSIP
N/A
CIK
1536196
Web
www.canfite.com
Phone
972-3-924-1114
Fax
972-3924-9378
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+768.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,170,000.00
Net Margins
-1,231.78%
Pretax Margin
-1,255.93%
Return on Equity
-143.29%
Return on Assets
-84.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.89
Quick Ratio
4.63

Sales & Book Value

Annual Sales
$810,000.00
Price / Sales
11.58
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.33 per share
Price / Book
1.99

Miscellaneous

Outstanding Shares
3,540,000
Free Float
3,512,000
Market Cap
$9.38 million
Optionable
Not Optionable
Beta
1.30
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Pnina Fishman Ph.D. (Age 75)
    Founder, Chief Scientific Officer & Exec. Chairman
    Comp: $644k
  • Mr. Motti Farbstein (Age 59)
    CEO & Chief Operating and Financial Officer
    Comp: $414k
  • Dr. Sari Fishman Ph.D. (Age 51)
    VP of Bus. Devel.
    Comp: $325k
  • Dr. Ilan Cohn Ph.D. (Age 69)
    Co-Founder & Director
  • Dr. Stephen A. Harrison FACP
    M.D., Member of Clinical Advisory Board & Consulting Chief Medical Officer

Key Competitors

View All Competitors













CANF Stock - Frequently Asked Questions

Should I buy or sell Can-Fite BioPharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CANF shares.
View CANF analyst ratings or view top-rated stocks.

What is Can-Fite BioPharma's stock price forecast for 2023?

2 equities research analysts have issued 1 year price targets for Can-Fite BioPharma's stock. Their CANF share price forecasts range from $12.00 to $34.00. On average, they predict the company's stock price to reach $23.00 in the next year. This suggests a possible upside of 768.0% from the stock's current price.
View analysts price targets for CANF or view top-rated stocks among Wall Street analysts.

How have CANF shares performed in 2023?

Can-Fite BioPharma's stock was trading at $0.6130 at the beginning of 2023. Since then, CANF shares have increased by 332.3% and is now trading at $2.6499.
View the best growth stocks for 2023 here.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) posted its earnings results on Thursday, August, 31st. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.14. The business earned $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. Can-Fite BioPharma had a negative trailing twelve-month return on equity of 143.29% and a negative net margin of 1,231.78%.

When did Can-Fite BioPharma's stock split?

Can-Fite BioPharma's stock reverse split on the morning of Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Can-Fite BioPharma's stock symbol?

Can-Fite BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "CANF."

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Can-Fite BioPharma's stock price today?

One share of CANF stock can currently be purchased for approximately $2.65.

How much money does Can-Fite BioPharma make?

Can-Fite BioPharma (NYSE:CANF) has a market capitalization of $9.38 million and generates $810,000.00 in revenue each year. The company earns $-10,170,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

How can I contact Can-Fite BioPharma?

Can-Fite BioPharma's mailing address is 10 Bareket Street, Kiryat Matalon PO Box 7537, Petah Tikva 4951778, Israel. The official website for the company is www.canfite.com. The company can be reached via phone at 972-3-924-1114, via email at info@canfite.co.il, or via fax at 972-3924-9378.

This page (NYSE:CANF) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -